• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials.

作者信息

Silverii Giovanni Antonio, Pala Laura, Cresci Barbara, Mannucci Edoardo

机构信息

Experimental and Clinical Biomedical Sciences 'Mario Serio' Department, University of Florence, Florence, Italy.

Diabetology Unit, AOU Careggi, Florence, Italy.

出版信息

Diabetes Obes Metab. 2025 Feb;27(2):1005-1009. doi: 10.1111/dom.16076. Epub 2024 Nov 20.

DOI:10.1111/dom.16076
PMID:39563616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11701179/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecb5/11701179/021680fb5f4d/DOM-27-1005-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecb5/11701179/021680fb5f4d/DOM-27-1005-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecb5/11701179/021680fb5f4d/DOM-27-1005-g001.jpg

相似文献

1
Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials.胰高血糖素样肽1（GLP1）受体激动剂与缺血性视神经病变风险：一项随机对照试验的荟萃分析
Diabetes Obes Metab. 2025 Feb;27(2):1005-1009. doi: 10.1111/dom.16076. Epub 2024 Nov 20.
2
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.胰高血糖素样肽-1 受体激动剂（胰腺炎、胰腺癌和胆石症）的安全性问题：来自随机对照试验的数据。
Diabetes Obes Metab. 2017 Sep;19(9):1233-1241. doi: 10.1111/dom.12926. Epub 2017 Jun 20.
3
Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病中的微血管作用：一项随机对照试验的荟萃分析。
Acta Diabetol. 2017 Oct;54(10):933-941. doi: 10.1007/s00592-017-1031-9. Epub 2017 Jul 27.
4
Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂替尔泊肽对2型糖尿病患者心率的影响：一项系统评价及成对和网状荟萃分析
Diabetes Obes Metab. 2024 Feb;26(2):548-556. doi: 10.1111/dom.15342. Epub 2023 Oct 20.
5
Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽 1 受体激动剂对心血管和肾脏结局影响的种族、民族和地域差异：心血管结局试验的系统评价和荟萃分析。
J R Soc Med. 2024 Aug;117(8):267-283. doi: 10.1177/01410768231198442. Epub 2023 Sep 21.
6
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.胰高血糖素样肽 1 受体激动剂在伴有或不伴有慢性心力衰竭的 2 型糖尿病患者中的应用：一项随机安慰剂对照结局试验的荟萃分析。
Diabetes Obes Metab. 2023 Jun;25(6):1495-1502. doi: 10.1111/dom.14997. Epub 2023 Feb 20.
7
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.接受胰高血糖素样肽-1 受体激动剂治疗的患者的主要心血管事件、心力衰竭和心房颤动：随机对照试验的更新荟萃分析。
Nutr Metab Cardiovasc Dis. 2020 Jun 25;30(7):1106-1114. doi: 10.1016/j.numecd.2020.03.013. Epub 2020 Mar 25.
8
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.胰高血糖素样肽-1 受体激动剂与 2 型糖尿病患者急性胰腺炎风险的关系。
Diabetes Obes Metab. 2017 Jun;19(6):906-908. doi: 10.1111/dom.12885. Epub 2017 Mar 17.
9
Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.使用胰高血糖素样肽-1 受体激动剂与骨折：一项随机临床试验的荟萃分析。
J Diabetes. 2014 May;6(3):260-6. doi: 10.1111/1753-0407.12102. Epub 2013 Nov 22.
10
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.胰高血糖素样肽-1 受体激动剂对体重减轻的影响：随机对照试验的系统评价和荟萃分析。
BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771.

引用本文的文献

1
Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes.司美格鲁肽或替尔泊肽与2型糖尿病患者的视神经及视觉通路疾病
JAMA Netw Open. 2025 Aug 1;8(8):e2526327. doi: 10.1001/jamanetworkopen.2025.26327.
2
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions.胰高血糖素样肽-1受体激动剂的作用扩展：当前证据及未来方向的叙述性综述
EClinicalMedicine. 2025 Jul 17;86:103363. doi: 10.1016/j.eclinm.2025.103363. eCollection 2025 Aug.
3
GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review.

本文引用的文献

1
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.司美格鲁肽处方治疗患者发生非动脉炎性前部缺血性视神经病变的风险。
JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296.
2
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
3
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
胰高血糖素样肽-1受体激动剂在治疗糖尿病相关合并症中的疗效：一项叙述性综述
J Diabetes Metab Disord. 2025 Apr 1;24(1):92. doi: 10.1007/s40200-025-01604-w. eCollection 2025 Jun.
4
Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.司美格鲁肽与非动脉炎性前部缺血性视神经病变：对已报道关联的综述与解读
Acta Ophthalmol. 2025 Mar 8. doi: 10.1111/aos.17473.
5
Are synthetic incretins associated with ischaemic optic neuropathy?合成肠促胰岛素与缺血性视神经病变有关吗？
Eye (Lond). 2025 Apr;39(5):808-809. doi: 10.1038/s41433-025-03718-0. Epub 2025 Feb 15.
司美格鲁肽治疗肥胖相关性心力衰竭合并 2 型糖尿病患者的效果。
N Engl J Med. 2024 Apr 18;390(15):1394-1407. doi: 10.1056/NEJMoa2313917. Epub 2024 Apr 6.
4
Reexamining the Incidence of Nonarteritic Anterior Ischemic Optic Neuropathy: A Rochester Epidemiology Project Study.重新审视非动脉炎性前部缺血性视神经病变的发病率：罗切斯特流行病学项目研究。
J Neuroophthalmol. 2024 Sep 1;44(3):337-341. doi: 10.1097/WNO.0000000000002102. Epub 2024 Feb 15.
5
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
6
A revolution in obesity treatment.肥胖治疗的一场革命。
Nat Med. 2023 Oct;29(10):2406-2408. doi: 10.1038/s41591-023-02538-7.
7
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.新一代抗糖尿病药物对糖尿病视网膜病变的影响：批判性评价。
Graefes Arch Clin Exp Ophthalmol. 2024 Mar;262(3):717-752. doi: 10.1007/s00417-023-06236-5. Epub 2023 Sep 20.
8
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.司美格鲁肽治疗射血分数保留的心力衰竭合并肥胖患者的疗效。
N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25.
9
Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention.2 型糖尿病患者的降糖药物心血管预防：初级和次级预防类别的循证方法。
Diabetes Obes Metab. 2023 Dec;25(12):3435-3443. doi: 10.1111/dom.15226. Epub 2023 Aug 2.
10
Prevalence of Diabetic Retinopathy in the US in 2021.2021 年美国糖尿病视网膜病变的患病率。
JAMA Ophthalmol. 2023 Aug 1;141(8):747-754. doi: 10.1001/jamaophthalmol.2023.2289.